

Statement of Advice:

**elvitegravir 150mg / cobicistat 150mg / emtricitabine 200mg / tenofovir
alafenamide 10mg (Genvoya®) SMC No 1323/18**
Gilead Sciences Ltd

9 February 2018

ADVICE: in the absence of a submission from the holder of the marketing authorisation

elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman
Scottish Medicines Consortium